Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Graefe's Archive for Clinical and Experimental Ophthalmology
Published in: Graefe's Archive for Clinical and Experimental Ophthalmology 7/2016

Open Access 01-07-2016 | Review Article

Retinal vein occlusion and the use of a dexamethasone intravitreal implant (Ozurdex®) in its treatment

Authors: Justus G. Garweg, Souska Zandi

Published in: Graefe's Archive for Clinical and Experimental Ophthalmology | Issue 7/2016

Login to get access

Abstract

Purpose

To review published data pertaining to the clinical experience with a dexamethasone intravitreal implant (Ozurdex®) with a view to establishing a clinically based therapeutic regime.

Methods

A PubMed search using the MeSH terms “retinal vein occlusion” and either “pathophysiology” or “dexamethasone intravitreal implant” was undertaken for manuscripts published until August 2015. The analysis included studies involving minimally 15 patients under a prospective design or 30 under a retrospective design, a minimal follow up of 6 months, and at least 2 intravitreal Ozurdex® injections per eye.

Results

In the vast majority of eyes, satisfactory outcomes were achieved with retreatment intervals of between 3 and 5 months. Initial evidence indicates a similar efficacy compared to anti-VEGF therapies as a first-line treatment. Safety concerns associated with the long-term and repeated use of Ozurdex® are not borne out by clinical findings: its implantation is not associated with a sustained increase in intraocular pressure (IOP) over time or with the number of applications.

Conclusion

Compared with anti-VEGF therapies, the burden of retreatment is reduced. In patients with chronic macular edema not responsive to repetitive anti-VEGF therapies, the outcome after dexamethasone implant treatment is encouraging. However, these results are achieved at the expense of side effects typically associated with steroids: in up to 20 % of the Ozurdex®-treated patients, an elevation in IOP, which could be medically controlled in the majority of cases, and cataract formation or progression was observed.
Literature
1.
Hahn P, Fekrat S (2012) Best practices for treatment of retinal vein occlusion. Curr Opin Ophthalmol 23(3):175–81CrossRefPubMed
2.
Glanville J, Patterson J, McCool R et al (2014) Efficacy and safety of widely used treatments for macular oedema secondary to retinal vein occlusion: a systematic review. BMC Ophthalmol 14:7CrossRefPubMedPubMedCentral
3.
Wong TY, Scott IU (2010) Clinical practice, retinal-vein occlusion. N Engl J Med 363(22):2135–2144CrossRefPubMed
4.
Campochiaro PA, Brown DM, Awh CC et al (2011) Sustained benefits from Ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology 118(10):2041–2049CrossRefPubMed
5.
Heier JS, Campochiaro PA, Yau L et al (2012) Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. Ophthalmology 119(4):802–809CrossRefPubMed
6.
Holz FG, Roider J, Ogura Y et al (2013) VEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study. Br J Ophthalmol 97(3):278–284CrossRefPubMed
7.
Brown DM, Heier JS, Clark WL et al (2013) Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study. Am J Ophthalmol 155(3):429–437CrossRefPubMed
8.
Noma H, Funatsu H, Mimura T et al (2009) Vitreous levels of interleukin-6 and vascular endothelial growth factor in macular edema with central retinal vein occlusion. Ophthalmology 116(1):87–93CrossRefPubMed
9.
Nguyen NX, Küchle M (1993) Aqueous flare and cells in eyes with retinal vein occlusion--correlation with retinal fluorescein angiographic findings. Br J Ophthalmol 77:280–3CrossRefPubMedPubMedCentral
10.
Tan CS, Chew MC, van Hemert J, Singer MA, Bell D, Sadda SR (2015) Measuring the precise area of peripheral retinal non-perfusion using ultra-widefield imaging and its correlation with the ischaemic index. Br J Ophthalmol.; pii:bjophthalmol-2015-306652
11.
The Central Vein Occlusion Study Group (1993) Baseline and early natural history report. Arch Ophthalmol 111(8):1087–1095CrossRef
12.
Noma H, Minamoto A, Funatsu H, Tsukamoto H, Nakano K, Yamashita H, Mishima HK (2006) Intravitreal levels of vascular endothelial growth factor and interleukin-6 are correlated with macular edema in branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 244(3):309–15CrossRefPubMed
13.
Koss MJ, Pfister M, Rothweiler F, Michaelis M, Cinatl J, Schubert R, Koch FH (2012) Comparison of cytokine levels from undiluted vitreous of untreated patients with retinal vein occlusion. Acta Ophthalmol 90(2):e98–e103
14.
Lee EK, Han JM, Hyon JY, Yu HG (2015) Changes in choroidal thickness after intravitreal dexamethasone implant injection in retinal vein occlusion. Br J Ophthalmol.; pii: bjophthalmol-2014-306417
15.
Glacet-Bernard A, Coscas G, Zourdani A et al. (2011) Steroids and macular edema from retinal vein occlusion. Eur J Ophthalmol.;21 Suppl 6:S37-44
16.
Whitcup SM, Robinson MR (2015) Development of a dexamethasone intravitreal implant for the treatment of noninfectious posterior segment uveitis. Ann N Y Acad Sci. doi:10.​1111/​nyas.​12824
17.
Coscas G, Augustin A, Bandello F et al (2014) Retreatment with Ozurdex for macular edema secondary to retinal vein occlusion. Eur J Ophthalmol 24(1):1–9
18.
Mayer WJ, Wolf A, Kernt M et al (2013) Twelve-month experience with Ozurdex for the treatment of macular edema associated with retinal vein occlusion. Eye (Lond) 27(7):816–22
19.
Demirel S, Yanık Ö, Batıoglu F, Özmert E, Bas Z (2015) Aqueous flare as an indicator of response to Dexamethasone treatment in retinal vein occlusions: a pilot study. Curr Eye Res 3:1–8
20.
Ip MS, Scott IU, VanVeldhuisen PC, Study Research Group SCORE et al (2009) A randomized trial comparing the efficacy and safety of Intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the standard care vs corticosteroid for retinal vein occlusion (SCORE) study report 5. Arch Ophthalmol 127(9):1101–14
21.
Scott IU, Ip MS, Van Veldhuisen PC, Study Research Group SCORE et al (2009) A randomized trial comparing the efficacy and safety of Intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to branch retinal vein occlusion: the standard care vs corticosteroid for retinal vein occlusion (SCORE) study report 6. Arch Ophthalmol 127(9):1115–28
22.
Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jiao J, Li XY, Whitcup SM, Li J, Ozuredx GENEVA Study Group (2011) Dexamethasone Intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology 118(12):2453–60
23.
London NJ, Chiang A, Haller JA (2011) The dexamethasone drug delivery system: indications and evidence. Adv Ther 28(5):351–66
24.
Joshi L, Yaganti S, Gemenetzi M, Lightman S, Lindfield D, Liolios V, Menezo V, Shao E, Taylor SR (2013) Dexamethasone implants in retinal vein occlusion: 12-month clinical effectiveness using repeat injections as-needed. Br J Ophthalmol 97(8):1040–4
25.
Augustin AJ, Holz FG, Haritoglou C, Mayer WJ, Bopp S, Scheuerle AF, Maier M, Sekundo W, Sandner D, Shirlaw A, Hattenbach LO (2015) Retrospective, observational study in patients receiving a dexamethasone intravitreal implant 0.7 mg for macular oedema secondary to retinal vein occlusion. Ophthalmologica 233:18–26
26.
Bandello F, Parravano M, Cavallero E, Cascavilla ML, Triolo G, Querques L, Borrelli E, Giorno P, Varano M, Lattanzio R, Querques G (2015) Prospective evaluation of morphological and functional changes after repeated intravitreal dexamethasone implant (Ozurdex®) for retinal vein occlusion. Ophthalmic Res 53:207–16
27.
Bezatis A, Spital G, Höhn F, Maier M, Clemens CR, Wachtlin J, Lehmann F, Hattenbach LO, Feltgen N, Meyer CH (2013) Functional and anatomical results after a single Intravitreal ozurdex injection in retinale vein occlusion: a 6-month follow-up- the SOLO study. Acta Opthalmol 91(5):e340–7
28.
Fortoul V, Denis P, Kodjikian L (2015) Anatomical and functional recurrence after Dexamethasone Intravitreal implants: a 6-month prospective study. Eye (Lond) 29:769–75
29.
Capone A Jr, Singer MA, Dodwell DG et al (2014) Efficacy and safety of two or more dexamethasone intravitreal implant injections for treatment of macular edema related to retinal vein occlusion (Shasta study). Retina 34(2):342–51
30.
Singer MA, Capone A Jr, Dugel PU, Dreyer RF, Dodwell DG, Roth DB, Shi R, Walt JG, Scott LC, Hollander DA, SHASTA Study Group (2015) Two or more dexamethasone intravitreal implants as monotherapy or in combination therapy for macular edema in retinal vein occlusion: subgroup analysis of a retrospective chart review study. BMC Ophthalmol 15:33
31.
Querques L, Querques G, Lattanzio R et al (2013) Repeated intravitreal dexamethasone implant (Ozurdex®) for retinal vein occlusion. Ophthalmologica 229(1):21–5
32.
Querques G, Cascavilla ML, Cavallero E et al (2014) Changes in macular function after ozurdex for retinal vein occlusion. Optom Vis Sci 91(7):760–8
33.
Schmitz K, Maier M, Clemens CR, Group GRVO et al (2014) Reliability and safety of Intravitreal ozurdex injections. The ZERO study. Ophthalmologe 111(1):44–52
34.
Iu LP, Zhao P, Yeung IY et al. (2014) Sequential therapy with ranibizumab and dexamethasone intravitreal implant is better than dexamethasone monotherapy for macular oedema due to retinal vein occlusion. Br J Ophthalmol.;pii: bjophthalmol-2014-305661
35.
Singer MA, Bell DJ, Woods P et al (2012) Effect of combination therapy with Bevacizumab and Dexamethasone Intravitreal implant in patients with retinal vein occlusion. Retina 32(7):1289–94
36.
Jonas JB, Spandau UH, Kamppeter BA, Vossmerbaeumer U, Harder B, Sauder G (2006) Repeated Intravitreal high-dosage injections of triamcinolone acetonide for diffuse diabetic macular edema. Ophthalmology 113(5):800–4
37.
Parodi MB, Iacono P, Campa C, La Spina C, Triolo G, Lattanzio R, Bandello F (2014) Dexamethasone tachyphylaxis in the treatment of macular oedema. Acta Ophthalmol 92(3):e243–4
38.
Matonti F, Hoffart L, Baeteman C, Denis D (2012) Repeated treatment for macular edema in vein occlusion by intravitreal implant of dexamethasone. Case Rep Ophthalmol 3(3):339–42
39.
Unsal E, Eltutar K, Sultan P, Gungel H (2015) The efficiency of Intravitreal Dexamethasone implants in the treatment of macular edema secondary to retinal vein occlusion. J Ocul Pharmacol Ther 31(6):350–6
40.
Parodi MB, Iacono P, De Benedetto U, Cascavilla M, Bandello F (2012) Rebound effect after intravitreal dexamethasone implant for the treatment of macular edema secondary to central retinal vein occlusion. J Ocul Pharmacol Ther 28(6):566–8
41.
Marticorena J, Romano MR, Heimann H, Stappler T, Gibran K, Groenewald C, Pearce I, Wong D (2011) Intravitreal bevacizumab for retinal vein occlusion and early growth of epiretinal membrane: a possible secondary effect? Br J Ophthalmol 95(3):391–5
42.
Hung KH, Lee SM, Lee SY, Lee FL, Yang CS (2010) Intravitreal bevacizumab (avastin) in the treatment of macular edema associated with perfused retinal vein occlusion. J Ocul Pharmacol Ther 26(1):85–90
43.
Alshahrani ST, Dolz-Marco R, Gallego-Pinazo R, Diaz-Llopis M, Arevalo JF; KKESH International Collaborative Retina Study Group (2015) intravitreal dexamethasone implant for the treatment of refractory macular edema in retinal vascular diseases: Results of the KKESH International Collaborative Retina Study Group. Retina
44.
Ozkok A, Saleh OA, Sigford DK, Heroman JW, Schaal S (2015) The Omar study: comparison of ozurdex and triamcinolone acetonide for refractory cystoid macular edema in retinal vein occlusion. Retina 35(7):1393–400
45.
Gado AS, Macky TA (2014) Dexamethasone intravitreous implant versus bevacizumab for central retinal vein occlusion-related macular oedema: a prospective randomized comparison. Clin Experiment Ophthalmol 42(7):650–5
46.
Matonti F, Meyer F, Guigou S et al (2013) Ozurdex in the management of the macular edema following retinal vein occlusion in clinical practice. Acta Ophthalmol 91(7):e584–6
47.
Mayer WJ, Hadjigoli A, Wolf A, Herold T, Haritoglou C (2015) Comparison of Intravitreal Dexamethasone Implant versus Intravitreal Ranibizumab as a First-Line Treatment of Macular Oedema due to Retinal Vein Occlusion. Klin Monatsbl Augenheilkd
48.
Yumusak E, Buyuktortop N, Ornek K (2015) Early results of dexamethasone implant, ranibizumab, and triamcinolone in macular edema due to branch retinal vein occlusion. Eur J Ophthalmol.;11:0
49.
Chiquet C, Dupuy C, Bron AM, Aptel F, Straub M, Isaico R, Romanet JP, Creuzot-Garcher C (2015) Intravitreal dexamethasone implant versus anti-VEGF injection for treatment-naïve patients with retinal vein occlusion and macular edema: a 12-month follow-up study. Graefes Arch Clin Exp Ophthalmol
50.
Nghiem-Buffet S, Fajnkuchen F, Buffet M, Ayrault S, Le Gloahec-Lorcy A, Grenet T, Delahaye-Mazza C, Quentel G, Cohen SY (2014) Intravitreal ranibizumab and/or dexamethasone implant for macular edema secondary to retinal vein occlusion. Ophthalmologica 232(4):216–22
51.
Parodi MB, Iacono P, Petruzzi G, Parravano M, Varano M, Bandello F (2015) Dexamethasone implant for macular edema secondary to ischemic retinal vein occlusions. Retina 35(7):1387–92
52.
Maggio E, Polito A, Guerriero M, Pertile G (2014) Intravitreal dexamethasone implant for macular edema secondary to retinal vein occlusion: 12-month follow-up and prognostic factors. Ophthalmologica 232(4):207–15
53.
Battaglia Parodi M, Iacono P, Sacconi R, Parravano M, Varano M, Bandello F (2015) Dexamethasone implant for macular edema secondary to central retinal vein occlusion in patients younger than 50 years. Retina 35(7):1381–6
54.
Reid GA, Sahota DS, Sarhan M (2015) Observed complications from dexamethasone intravitreal implant for the treatment of macular edema in retinal vein occlusion over 3 treatment rounds. Retina 35(8):1647–55
55.
Caillaux V, Valtot F, Souied EH, Mimoun G (2015) Intraocular pressure after intravitreal injection of dexamethasone implant for macular edema resulting from retinal vein occlusion. Eur J Ophthalmol.;30;25(5):454–8
56.
Boyer DS, Yoon YH, Belfort R Jr, Ozurdex MEAD Study Group et al (2014) Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology 121(10):1904–14
Metadata
Title
Retinal vein occlusion and the use of a dexamethasone intravitreal implant (Ozurdex®) in its treatment
Authors
Justus G. Garweg
Souska Zandi
Publication date
01-07-2016
Publisher
Springer Berlin Heidelberg
Published in
Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 7/2016
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI
https://doi.org/10.1007/s00417-016-3350-x

Other articles of this Issue 7/2016

Graefe's Archive for Clinical and Experimental Ophthalmology 7/2016 Go to the issue

Letter to the Editor

Split-cornea transplantation — a microbiologically safe approach?

Letter to the Editor (by invitation)

Response to comment on: Relative changes in luminal and stromal areas of choroid determined by binarization of EDI-OCT images in eyes with Vogt-Koyanagi-Harada disease after treatment

Refractive Surgery

In vitro optical quality comparison between the Mini WELL Ready progressive multifocal and the TECNIS Symfony

Retinal Disorders

ANGPTL-4 correlates with vascular endothelial growth factor in patients with proliferative diabetic retinopathy

Letter to the Editor

Comment on: Relative changes in luminal and stromal areas of choroid determined by binarization of EDI-OCT images in eyes with Vogt-Koyanagi-Harada disease after treatment

Letter to the Editor (by invitation)

The possible mechanisms of subretinal fluid resolution after vitrectomy